ArticleHealth affairs scholar2025
Measuring commercial cannabis availability: findings from a multi-state surveillance study in the US.
Article in Health affairs scholar, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cannabis legalization enables greater access to commercial cannabis among adults. Little is known about the extent to which demand for cannabis is met by licit or illicit markets among states with medical-only or recreational cannabis laws, or no legalization. Methods: Annual sales values of medical and recreational tetrahydrocannabinol (THC), illicit THC, hemp-derived cannabidiol (CBD) and hemp-derived THC were estimated for 2024 in 12 US states by combining and triangulating data from national- and state-level public sources, Euromonitor's Passport database, in-store audits ( Results: State-level THC market size was substantial, accounting for ≥90% of the combined cannabis market value of THC and CBD, regardless of legalization status. However, the composition of THC markets-across legal recreational, medical, illicit, and hemp-derived segments-varied considerably, even among states with the same legalization status. Conclusions: The emergence of hemp-derived THC in both legal and non-legal markets alongside the persistence of illicit THC sales in legal markets highlight regulatory gaps and challenges in market oversight. These findings underscore the need for integrated policy approaches that align enforcement strategies with public health objectives and consumer education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.